Major cardiovascular outcome trials include: LEADER trial (liraglutide): Demonstrated a significant reduction in major adverse cardiovascular events (MACE) in patients with type 2 diabetes and high cardiovascular risk SUSTAIN-6 (semaglutide): Showed reduced cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke REWIND (dulaglutide): Confirmed cardiovascular benefits across a broad patient population SELECT trial (semaglutide): Showed reduced MACE in people with obesity without diabetes, though this evidence is not yet fully incorporated into UK labelling [17] These trials consistently found that the modest heart rate increases observed did not translate into adverse cardiovascular outcomes
Once those baseline labs are getting established, so sometimes, you know, with a patient, I'll be like, you got your blood drawn
Clinical monitoring for therapeutic effect is advisable, especially during initiation
How Do Reviews Change as Platforms Scale
What is Ozempic burp, and how can I reduce it
Trust and Transparency Many users appreciate the fast sign-up and competitive pricing, though some report delays in support and confusion around billing